Scan brief descriptions of cost-effectiveness analyses conducted by our center community and our decision science colleagues across the globe.

Stephane Verguet speaking to someone off-camera

Value for Money Framework

How can we compare the value-for-money of different early childhood development (ECD) interventions? Using published data the authors compute the relative cost-effectiveness of ECD interventions intended to affect motor, cognitive, language and socioemotional skills.

Headshots of Allison Portnoy (top) and Nick Menzies (bottom)

Investment Case for TB Vaccines

When providing guidance for investment decisions and vaccine roll-out, it is important to analyze cost effectiveness, health equity, and macroeconomic impact. A World Health Organization (WHO) report outlines this for new tuberculosis (TB) vaccines in 105 LMICs.

Image of Stephen Resch Filming in the GHELI Studio.

Cost-Effectiveness Thresholds

Interventions that impose costs per DALY averted less than 3x and 1x GDP per capita are considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of this threshold.

Testing & Treating Latent TB

Testing and treating latent tuberculosis infections (LTBI) among the Medicare-eligible could lead to substantial reductions in TB and TB-related mortality. The incremental cost-effectiveness ratio of a one-time test and treat intervention is in the order of $109,000 per QALY gained.

Including Impoverishment with CEA

To improve prioritization for low income patients, a recent article developed a novel method to integrate medical impoverishment risk into healthcare priority setting in LMICs. It used weights based on financial risk protection and was able to distinguish moderately cost-effective interventions.

Borderline Cost-Effective Guidelines

A cost-effectiveness analysis of the 2022 guideline-directed therapy for heart failure with reduced ejection fraction (HFrEF) found that the addition of two newer medical therapies to standard of care were borderline cost-effective at the conventional cost-effectiveness threshold.